Wacker Biotech AG, of Munich, Germany, will produce the drug substance in Spectrila (asparaginase), a drug from its customer, Hamburg, Germany-based Medac Gesellschaft fur klinische Spezialpräparate mbhH, which was recently approved by the European Commission. The medication will be used for treating acute lymphocytic leukemia. Wacker developed the manufacturing process for the drug substance – recombinant L-asparaginase – from the initial cell line to commercial production.